Prenetics Global Limited (NASDAQ:PRE) Short Interest Up 46.2% in May

Prenetics Global Limited (NASDAQ:PRE) saw a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 34,500 shares, an increase of 46.2% from the May 15th total of 23,600 shares. Based on an average daily trading volume, of 21,200 shares, the short-interest ratio is currently 1.6 days. Currently, 0.4% of the company’s stock are short sold.

Institutional Trading of Prenetics Global

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. raised its stake in Prenetics Global Limited (NASDAQ:PRE) by 3.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 333,528 shares of the company’s stock after acquiring an additional 10,576 shares during the quarter. Nomura Holdings Inc. owned about 2.73% of Prenetics Global worth $1,307,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Prenetics Global Stock Performance

PRE remained flat at $7.01 on Monday. The company had a trading volume of 81,930 shares, compared to its average volume of 19,125. The company has a 50 day moving average price of $6.32 and a two-hundred day moving average price of $5.53. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $11.99. The company has a market cap of $85.56 million, a P/E ratio of -1.76 and a beta of 0.17.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings data on Thursday, June 12th. The company reported ($0.80) earnings per share (EPS) for the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. The company had revenue of $17.31 million for the quarter. On average, equities research analysts predict that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.